Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

ClinicalTrials.gov ID: NCT03992456

Public ClinicalTrials.gov record NCT03992456. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 21, 2026, 12:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

PULSE: A Randomized, Phase II Open Label Study of PanitUmumab RechaLlenge Versus Standard Therapy After Progression on Anti-EGFR Therapy in Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

Study identification

NCT ID: NCT03992456
Recruitment status: Not listed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Academic and Community Cancer Research United; Other
Enrollment: 12 participants

Conditions and interventions

Conditions

Interventions

Panitumumab Biological
Quality-of-Life Assessment Other
Questionnaire Administration Other
Regorafenib Drug
Trifluridine and Tipiracil Hydrochloride Drug

Biological · Other · Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 23, 2020
Primary completion: Nov 30, 2023
Completion: Oct 6, 2024
Last update posted: May 20, 2024

2020 – 2024

United States locations

U.S. sites: 18
U.S. states: 13
U.S. cities: 14

Facility	City	State	ZIP	Site status
Mayo Clinic in Arizona	Scottsdale	Arizona	85259	—
UC San Diego Moores Cancer Center	La Jolla	California	92093	—
USC / Norris Comprehensive Cancer Center	Los Angeles	California	90033	—
Cedars Sinai Medical Center	Los Angeles	California	90048	—
MedStar Georgetown University Hospital	Washington D.C.	District of Columbia	20007	—
MedStar Washington Hospital Center	Washington D.C.	District of Columbia	20010	—
Mayo Clinic in Florida	Jacksonville	Florida	32224-9980	—
Emory University Hospital/Winship Cancer Institute	Atlanta	Georgia	30322	—
University of Chicago Comprehensive Cancer Center	Chicago	Illinois	60637	—
Massachusetts General Hospital Cancer Center	Boston	Massachusetts	02114	—
Brigham and Women's Hospital	Boston	Massachusetts	02115	—
Dana-Farber Cancer Institute	Boston	Massachusetts	02215	—
Mayo Clinic in Rochester	Rochester	Minnesota	55905	—
Rutgers Cancer Institute of New Jersey	New Brunswick	New Jersey	08903	—
Duke University Medical Center	Durham	North Carolina	27710	—
Allegheny General Hospital	Pittsburgh	Pennsylvania	15212	—
M D Anderson Cancer Center	Houston	Texas	77030	—
Aurora Cancer Care-Milwaukee West	Wauwatosa	Wisconsin	53226	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03992456, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 20, 2024 · Synced May 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03992456 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →